FDA Panel Rejects MDMA Therapy for PTSD
TL;DR Summary
An FDA advisory panel voted 9-2 against approving MDMA for PTSD treatment, citing concerns over clinical trial methodology and therapist oversight, and 10-1 against the benefits outweighing the risks under the proposed REMS program.
- MDMA therapy for PTSD voted down by FDA advisory panel - STAT STAT
- FDA advisors reject MDMA as treatment for PTSD : Shots - Health News NPR
- The psychedelic medicine revolution just took a big loss POLITICO
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
- FDA advisers vote against first MDMA therapy to treat PTSD CNN
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
85%
233 → 34 words
Want the full story? Read the original article
Read on STAT